NBIX
Neurocrine Biosciences, Inc.
Platform & Compounding FCF
B+
77.9 / 100 composite
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
-
5yr Avg ROIC
7.5%
-
Operating Margin Trend
+3.27 pp/yr
-
5yr Avg ROE
8.1%
-
5yr Share-Count CAGR
1.2%
-
5yr Revenue CAGR
26.0%
-
5yr EPS CAGR
50.1%
-
Revenue-Growth Years (5)
5/5
-
5yr FCF Margin
22.2%
-
5yr FCF/NI Conversion
1.87x
-
Net Debt / EBITDA
-1.60x
-
Interest Coverage (EBIT/Int)
30.00x
-
Altman Z-Score
8.07
Stability
Weight: 5%
C-
46
-
EPS Volatility (σ/μ)
0.77
-
Piotroski F-Score
5
-
Negative-Revenue Years (5)
0/5
3 of 3 gurus held; 1 new buy; 1 added; 1 trimmed.
- Holders
- 3
+1
- Avg Δ position
-
+56.2%
- New buys
- 1
- Full exits
- 0